Dirk Sibbing/LinkedIn
Nov 17, 2025, 05:31
Dirk Sibbing: New Data Strengthen the Case for Prasugrel in ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Following ISAR-REACT 5 and the recently published large Danisch registry in > 10,000 pts more data is accumulating that benefits praugrel over ticagrelor for PCI in ACS patients.
See the interesting coverage and analysis with comments from Sripal Bangalore and Ajay Kirtane on TCTMD on TUXEDO-2, a randomized comparison that focused on diabetic patients with multivessel disease undergoing PCI.”
Find more information here.
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera